Skip to content

Blocking Sphenopalatine Ganglion by Intranasal Lidocaine Spray in Partial Turbinectomy Surgeries

Efficacy of Intranasal Sphenopalatine Ganglion Block by Lidocaine Spray for Partial Turbinectomy Surgeries

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07299630
Acronym
SPG block
Enrollment
50
Registered
2025-12-23
Start date
2025-12-20
Completion date
2026-05-30
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Turbinate Surgery, Sphenopalatine Block

Keywords

SPG block, lidocaine spray, partial turbinectomy surgery

Brief summary

Nasal turbinectomy surgeries are usually done as day case surgeries as most patients are young with unremarkable comorbidities. However, considerations are still present towards patients of old age or those suffering from obesity or obstructive sleep apnea (OSA). Different techniques are still evolving to improve handling those patients to decrease complications, enhance recovery after surgery and increase patient satisfaction. Targeting sphenopalatine ganglion block by topical local anesthesia is a proposed technique that could help by decreasing peri-operative opioid consumption.

Detailed description

Patients undergoing turbinectomy usually suffer from chronic nasal congestion with wide spectrum of symptoms ranging from headache and breathing difficulty to sleep disorders and obstructive sleep apnea that could affect daily life . Usually the surgery is done as a day case surgery in patients without major comorbidities. Points of concern to achieve smooth outcome and enhance recovery include pain management, better surgical field for both patient and surgeon satisfaction. One approach for these goals include regional nerve blocks for the innervation of the nose . Spheno Palatine Ganglion (SPG) block was tested with a good results for blocking autonomic innervation and subsequent decrease in pain and opioid consumption. Blockage of SPG has many approaches either trans nasal or trans oral but both are invasive and needs trained hands to do Locally infiltrating lidocaine over nasal mucosa either by lidocaine spray or a lidocaine soaked gauze was also tested in nasal surgeries with good results but doubts about duration of action of lidocaine spray is a concern that may affect post-operative pain management Targeting SPG noninvasively by lidocaine spray is proposed technique that may offer easier approach for this type of surgeries. Although concerns about effectiveness of the spray to reach and block SPG was raised before , many studies examined this approach to control headache or trigeminal neuralgia with great success.

Interventions

Standardized general anaesthesia with fentanyl 2 mcg/kg ABW at induction, propofol 1.5 mg/kg, rocuronium 0.6 mg/kg, sevoflurane 1 MAC for maintenance, followed by morphine 0.05 mg/kg ABW after intubation and nasal decongestant application. Intraoperative rescue fentanyl 50 mcg IV for tachycardia or hypertension exceeding 20% above baseline, repeatable after 10 minutes. Postoperative paracetamol 1g IV every 8 hours and pethidine 50 mg IV for VAS greater than 4.

Identical general anaesthesia induction and maintenance as the control arm. After intubation and bilateral xylometazoline nasal decongestant: intranasal lidocaine 10% spray 10 puffs per nostril bilaterally, directed parallel to the nasal floor in a postero-superior direction until resistance is felt, targeting the sphenopalatine fossa. Total dose not to exceed 3 mg/kg ABW. Identical rescue and postoperative analgesia as control arm.

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

A two-anesthesiologist model will be employed to achieve investigator blinding. Anesthesiologist 1 (unblinded) will open the sealed randomization envelope and administer the allocated intervention after induction and nasal decongestant application, then withdraw from all further patient care and data recording for that case. Anesthesiologist 2 (blinded) will assume full intraoperative management after intervention administration is complete, recording all vital signs, haemodynamic events, and rescue analgesic doses without knowledge of group allocation. A third anesthesiologist (Anesthesiologist 3, blinded) with no involvement in intraoperative care will conduct all postoperative assessments including VAS-Pain scoring, pethidine administration, and recovery timing from recovery room arrival to 12 hours postoperatively. Patient blinding is ensured by administering all group-specific interventions after induction of general anaesthesia and loss of consciousness. The operating surgeon is

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Undergoing elective partial turbinectomy surgery * Age 18 years or older

Exclusion criteria

* Patient refusal * Kidney or liver impairment * Pregnant or breast-feeding women * Allergy to any of the drugs used in the study * OR time more than 90 minutes (defined as time from anaesthesia induction to end of surgery, excluding extubation time)

Design outcomes

Primary

MeasureTime frameDescription
Fentanyl dosesIntraoperativeTotal cumulative intraoperative fentanyl rescue dose (mcg) administered in response to tachycardia defined as heart rate exceeding 20% above individual baseline or hypertension defined as systolic blood pressure exceeding 20% above individual baseline, given in increments of 50 mcg intravenously and repeatable every 10 minutes if the triggering criterion persists.

Secondary

MeasureTime frameDescription
Visual analog ScoreUp to 12 hours post operativePostoperative pain intensity will be assessed using the Visual Analogue Scale for Pain (VAS-Pain), a unidimensional 10-point numerical scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain; higher scores indicate worse pain outcome. VAS-Pain will be assessed at four prespecified timepoints: recovery room arrival, 2 hours, 6 hours, and 12 hours postoperatively, by a blinded outcomes assessor. Rescue analgesia with pethidine 50 mg intravenously will be administered for VAS-Pain score greater than 4.
Intraoperative TachycardiaIntraoperativeNumber of patients experiencing at least one episode of heart rate exceeding 20% above individual baseline intraoperative heart rate, recorded by continuous ECG monitoring with non-invasive readings documented every 5 minutes from T0 to end of surgery
Intraoperative HypertensionIntraoperativeNumber of patients experiencing at least one episode of systolic blood pressure exceeding 20% above individual baseline systolic blood pressure, recorded by non-invasive blood pressure monitoring every 5 minutes from T0 to end of surgery
Total Postoperative PethidineUp to 12 hours postoperativeCumulative dose of pethidine in milligrams administered intravenously in response to Visual Analogue Scale score greater than 4, recorded from recovery room arrival to 12 hours postoperatively by a blinded outcomes assessor
Time to ExtubationImmediate postoperative periodTime in minutes from end of surgery to successful tracheal extubation, assessed by the blinded outcomes assessor
Time to Aldrete Score ≥9Immediate postoperative periodTime in minutes from tracheal extubation to attainment of a modified Aldrete score of 9 or above, indicating readiness for discharge from the post-anaesthesia care unit, assessed by the blinded outcomes assessor

Countries

Egypt

Contacts

CONTACTAbdallah soudi, M.D.
dr.soudi2014@med.asu.edu.eg02- 01111228925

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026